Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.50
+0.17 (1.28%)
At close: Jun 8, 2026, 4:00 PM EDT
13.24
-0.26 (-1.93%)
After-hours: Jun 8, 2026, 7:15 PM EDT

Trevi Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Trevi Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $23.9. The average 1-year stock price forecast is 77.04% higher than the current stock price, while the lowest is $20 (+48.15%) and the highest is $30 (+122.22%).

Price Target: $23.9 (+77.04%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$20$23.9$24$30
Change+48.15%+77.04%+77.78%+122.22%

Analyst Ratings

The average analyst rating for Trevi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy999998
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total111111111110

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Needham
Needham
Buy
Maintains
$23
BuyMaintains$23+70.37%May 20, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$24
BuyReiterates$24+77.78%May 8, 2026
Clear Street
Clear Street
Buy
Maintains
$21$29
BuyMaintains$21$29+114.81%May 7, 2026
JonesTrading
JonesTrading
Buy
Maintains
$24
BuyMaintains$24+77.78%May 7, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Reiterates
$18$30
BuyReiterates$18$30+122.22%May 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.47
from -0.32
EPS Next Year
-0.56
from -0.47
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-32.48M-29.91M-33.92M-51.52M-49.33M-80.12M
Net Income
-33.94M-29.15M-29.07M-47.91M-42.76M-76.65M
EPS
-----0.32-0.47
Free Cash Flow
-16.50M-17.95M-21.97M-21.03M-27.86M-82.26M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-
Avg-0.47
Low-

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-